BMS Does Not Think Pricing Or Monitoring Will Limit Camzyos Use
First-In-Class Drug’s List Price Is $89,500 Per Year
Executive Summary
Bristol already is training cardiologists at major treatment centers in how to treat obstructive hypertrophic cardiomyopathy with Camzyos (mavacamten) based on the REMS in the US label.
You may also be interested in...
BMS’s Revlimid Loss Of Exclusivity Is Not As Bad As Expected, But Not For Long
The company credited generics’ late market entry, but that benefit is not expected to last; the firm lowered guidance for annual sales of the oncologic. The firm stressed growth opportunities ahead for Opdivo, Opdualag and Camzyos.
Bristol’s Mavacamten Shows Consistent Efficacy, Safe Use In Obstructive HCM At ACC
Long-term results from the EXPLORER-HCM extension study are consistent with the pivotal trial in obstructive hypertrophic cardiomyopathy, while data from VALOR may support a supplemental filing.
REMS For Mavacamten Could Involve Additional Monitoring, BMS Says
The FDA will take three more months to review mavacamten, a treatment for hypertrophic cardiomyopathy that BMS expects to be one of the company’s next blockbusters.